RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of β-catenin by interacting with βTrCP

被引:42
作者
Estrabaud, Emilie
Lassot, Irina
Blot, Guillaume
Le Rouzic, Erwann
Tanchou, Valerie
Quemeneur, Eric
Daviet, Laurent
Margottin-Goguet, Florence
Benarous, Richard
机构
[1] Inst Cochin Genet Mol, Dept Malad Infect, INSERM U567, F-75014 Paris, France
[2] CNRS, UMR 8104, Paris, France
[3] Univ Paris 05, Fac Med Rene Descartes, UMRS 8104, Paris, France
[4] Hybrigenics, Paris, France
[5] CEA Valrho, DSV, DIEP, SBTN, Bagnols Sur Ceze, France
关键词
D O I
10.1158/0008-5472.CAN-06-2530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Ras-association domain family 1 (RASSF1) gene has seven different isoforms; isoform A is a tumor-suppressor gene (RASSF1A). The promoter of RASSF1A is inactivated in many cancers, whereas the expression of another major isoform, RASSF1C, is not affected. Here, we show that RASSF1C, but not RASSF1A, interacts with beta TrCP. Binding of RASSF1C to beta TrCP involves serine 18 and serine 19 of the SS(18)GYXS(19) motif present in RASSF1C but not in RASSF1A. This motif is reminiscent of the canonical phosphorylation motif recognized by (dTrCP; however, surprisingly, the association between RASSF1C and TrCP does not occur via the beta TrCP substrate binding domain, the WD40 repeats. Overexpression of RASSF1C, but not of RASSF1A, resulted in accumulation and transcriptional activation of the beta-catenin oncogene, due to inhibition of its beta TrCP-mediated degradation. Silencing of RASSF1A by small interfering RNA was sufficient for (beta-catenin to accumulate, whereas silencing of both RASSFIA and RASSF1C had no effect. Thus, RASSF1A and RASSF1C have opposite effects on beta-catenin degradation. Our results suggest that RASSF1C expression in the absence of RASSF1A could play a role in tumorigenesis.
引用
收藏
页码:1054 / 1061
页数:8
相关论文
共 41 条
[1]   Role of the ras-association domain family 1 tumor suppressor gene in human cancers [J].
Agathanggelou, A ;
Cooper, WN ;
Latif, F .
CANCER RESEARCH, 2005, 65 (09) :3497-3508
[2]   Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter [J].
Ahmed-Choudhury, J ;
Agathanggelou, A ;
Fenton, SL ;
Ricketts, C ;
Clark, GJ ;
Maher, ER ;
Latif, F .
CANCER RESEARCH, 2005, 65 (07) :2690-2697
[3]   Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation [J].
Amaar, YG ;
Baylink, DJ ;
Mohan, S .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (08) :1430-1439
[4]   SCF-mediated protein degradation and cell cycle control [J].
Ang, XLL ;
Harper, JW .
ONCOGENE, 2005, 24 (17) :2860-2870
[5]   SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box [J].
Bai, C ;
Sen, P ;
Hofmann, K ;
Ma, L ;
Goebl, M ;
Harper, JW ;
Elledge, SJ .
CELL, 1996, 86 (02) :263-274
[6]   The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to bax conformational change and cell death [J].
Baksh, S ;
Tommasi, S ;
Fenton, S ;
Yu, VC ;
Martins, LM ;
Pfeifer, GP ;
Latif, F ;
Downward, J ;
Neel, BG .
MOLECULAR CELL, 2005, 18 (06) :637-650
[7]   Overexpression of human βTrCP1 deleted of its F box induces tumorigenesis in transgenic mice [J].
Belaïdouni, N ;
Peuchmaur, M ;
Perret, C ;
Florentin, A ;
Benarous, R ;
Besnard-Guèrin, C .
ONCOGENE, 2005, 24 (13) :2271-2276
[8]   β-catenin:: A pivot between cell adhesion and Wnt signalling [J].
Bienz, M .
CURRENT BIOLOGY, 2005, 15 (02) :R64-R67
[9]   A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter [J].
Brès, V ;
Kiernan, RE ;
Linares, LK ;
Chable-Bessia, C ;
Plechakova, O ;
Tréand, C ;
Emiliani, S ;
Peloponese, JM ;
Jeang, KT ;
Coux, O ;
Scheffner, M ;
Benkirane, M .
NATURE CELL BIOLOGY, 2003, 5 (08) :754-761
[10]   RASSFIA interacts with microtubule-associated proteins and modulates microtubule dynamics [J].
Dallol, A ;
Agathanggelou, A ;
Fenton, SL ;
Ahmed-Choudhury, J ;
Hesson, L ;
Vos, MD ;
Clark, GJ ;
Downward, J ;
Maher, ER ;
Latif, F .
CANCER RESEARCH, 2004, 64 (12) :4112-4116